Critical real‐world patient data observation of repurposable drugs from Alzheimer's disease drug development pipeline using Target Trial Emulation

Abstract

Background: Repurposing FDA‐approved drugs offers a promising strategy to accelerate the discovery of Alzheimer’s disease (AD) treatments. Numerous trials rely on fragmented evidence from observational studies and experiments suggesting potential benefits for AD. To address this, we used a large‐scale U.S.